Fouad Namouni Sells 3,633 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC opened at $88.61 on Friday. The firm has a market capitalization of $5.55 billion, a P/E ratio of -18.42 and a beta of 0.58. The firm’s 50-day moving average price is $92.59 and its 200-day moving average price is $98.96. The company has a current ratio of 3.71, a quick ratio of 3.65 and a debt-to-equity ratio of 1.06. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.49. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The business had revenue of $138.20 million for the quarter, compared to the consensus estimate of $104.02 million. During the same period in the prior year, the business earned ($2.19) EPS. The firm’s revenue for the quarter was up 139.9% on a year-over-year basis. Equities research analysts anticipate that Blueprint Medicines Co. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on BPMC. Morgan Stanley increased their price objective on Blueprint Medicines from $110.00 to $115.00 and gave the company an “equal weight” rating in a report on Friday, July 12th. Baird R W raised Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. Robert W. Baird lifted their price objective on Blueprint Medicines from $112.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Barclays upped their target price on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a report on Monday, July 29th. Finally, Needham & Company LLC restated a “buy” rating and set a $130.00 price target on shares of Blueprint Medicines in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $120.00.

Hedge Funds Weigh In On Blueprint Medicines

Large investors have recently modified their holdings of the company. Principal Financial Group Inc. raised its holdings in Blueprint Medicines by 331.9% during the first quarter. Principal Financial Group Inc. now owns 62,670 shares of the biotechnology company’s stock worth $5,945,000 after buying an additional 48,160 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Blueprint Medicines in the 1st quarter worth about $474,000. Vanguard Group Inc. lifted its position in Blueprint Medicines by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock valued at $564,045,000 after acquiring an additional 147,827 shares in the last quarter. Hsbc Holdings PLC acquired a new position in Blueprint Medicines during the 2nd quarter valued at about $1,060,000. Finally, Comerica Bank increased its holdings in Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock worth $1,028,000 after purchasing an additional 10,435 shares in the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.